The cells were expanded ex vivo and administered in a single infusion (1×106 or 2×106 CAR T cells per kilogram of body weight) after a conditioning regimen of cyclophosphamide and fludarabine...Conclusion TLR2-costimulated CAR T cell therapy for patients with R/R B cell malignancies with CNS involvement is safe, feasible, and results in high response rates and durable remission in both ALL and NHL patients with CNS disease. The clinical trial was registered at www.clinicaltrials.gov as # NCT04605666.
1 year ago
Clinical • CAR T-Cell Therapy
|
TLR2 (Toll Like Receptor 2)
|
CD19 positive
|
cyclophosphamide • fludarabine IV • CD19-CAR-T2 cells
P2, N=60, Recruiting, Nanfang Hospital of Southern Medical University | Trial completion date: Jun 2021 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Jun 2023
over 1 year ago
Trial completion date • Trial primary completion date • CAR T-Cell Therapy